Vascular Endothelial Cell Function in Catastrophic Antiphospholipid Syndrome: A Case Report and Review of the Literature
Author(s) -
Bertrand Routy,
Thuan Huynh,
R. Fraser,
Chantal Séguin
Publication year - 2013
Publication title -
case reports in hematology
Language(s) - English
Resource type - Journals
eISSN - 2090-6560
pISSN - 2090-6579
DOI - 10.1155/2013/710365
Subject(s) - medicine , catastrophic antiphospholipid syndrome , antiphospholipid syndrome , rituximab , pathophysiology , cardiogenic shock , cardiology , immunology , intensive care medicine , myocardial infarction , thrombosis , antibody
Catastrophic antiphospholipid syndrome (CAPS) is a rare autoimmune condition, which has been associated with a high mortality rate. However, with current management that includes a combination of anticoagulation, glucocorticoid administration, and plasma exchange, mortality rate has declined. Despite survival improvement with new generation immunosuppressive agents, their mechanisms of action are poorly defined, and CAPS is still considered a high-risk complication in patients known with antiphospholipid antibody syndrome. Herein, we present a case of a 79-year-old male who presented with a myocardial infarct and renal failure secondary to CAPS following a splenectomy for immune thrombocytopenia. Regardless of rapid combination of first-line treatment and rituximab therapy, the patient developed lethal cardiogenic shock secondary to mitral valve papillary muscle necrosis. Discussion of the pathophysiology and avenues of future therapies in CAPS are reported.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom